Atlas Trials

Study of Long-term Safety, Efficacy Tolerability of BYM338 in Patients With Sporadic Inclusion Body Myositis

Clinical trial NCT02250443 · COMPLETED

Trial details

NCT number
NCT02250443
Sponsor
Novartis Pharmaceuticals
Status
COMPLETED
Phase
Phase 2, Phase 3
Study type
INTERVENTIONAL
Sporadic Inclusion Body Myositis (sIBM)
Start date
2014-03-11
Primary completion
2016-08-23
Enrollment
10

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.